These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 29947083)

  • 1. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
    Portale AA; Carpenter TO; Brandi ML; Briot K; Cheong HI; Cohen-Solal M; Crowley R; Jan De Beur S; Eastell R; Imanishi Y; Imel EA; Ing S; Ito N; Javaid M; Kamenicky P; Keen R; Kubota T; Lachmann R; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Zhang L; Theodore-Oklota C; Mealiffe M; San Martin J; Insogna K
    Calcif Tissue Int; 2019 Sep; 105(3):271-284. PubMed ID: 31165191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
    Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
    J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review.
    Lafage-Proust MH
    Ther Adv Rare Dis; 2022; 3():26330040221074702. PubMed ID: 37180412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.
    Brandi ML; Jan de Beur S; Briot K; Carpenter T; Cheong HI; Cohen-Solal M; Crowley RK; Eastell R; Imanishi Y; Imel EA; Ing SW; Insogna K; Ito N; Javaid K; Kamenicky P; Keen R; Kubota T; Lachmann RH; Perwad F; Pitukcheewanont P; Portale A; Ralston SH; Tanaka H; Weber TJ; Yoo HW; Sun W; Williams A; Nixon A; Takeuchi Y
    Calcif Tissue Int; 2022 Oct; 111(4):409-418. PubMed ID: 35927518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.
    Baroncelli GI; Grandone A; Aversa A; Sessa MR; Pelosini C; Michelucci A; Toschi B; Manca M; Isola A; Comberiati P
    Eur J Med Genet; 2024 Aug; 70():104958. PubMed ID: 38950880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
    Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
    N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
    Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
    Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
    J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
    Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burosumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
    Balani S; Perwad F
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burosumab for Pediatric X-Linked Hypophosphatemia.
    Imel EA
    Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
    Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
    J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
    Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH
    Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X-Linked Hypophosphatemia: Results From the Phase 3, Single-Arm International Trial.
    Fratzl-Zelman N; Hartmann MA; Gamsjaeger S; Rokidi S; Paschalis EP; Blouin S; Zwerina J
    J Bone Miner Res; 2022 Sep; 37(9):1665-1678. PubMed ID: 35775373
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 42.